Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382613 · ClinicalTrials.gov registry record
A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation
A clinical trial, sponsored by Janssen Scientific Affairs.
- Terminated
- Registry status
- 2,000
- Enrollment target
NCT03382613: Clinical Trial study, sponsored by Janssen Scientific Affairs.
NCT03382613 is a clinical trial that was terminated before completion, run by Janssen Scientific Affairs. The registered enrollment target is 2,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03382613 was terminated before completion, sponsored by Janssen Scientific Affairs.
- TERMINATED
- Registry status
- 2,000 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of a hospital quality improvement (QI) program on the use of guideline-recommended oral anticoagulants (OAC) in hospitalized patients with atrial fibrillation (AF) at risk for ischemic stroke. Specifically, the study will determine whether the intervention, compared to Usual Care, will result in a greater increase in the proportion of patients with AF at risk for ischemic stroke who are appropriately treated with OAC.
Primary Outcome
The impact of a hospital quality improvement (QI) program on the use of guideline-recommended oral anticoagulants (OAC) in hospitalized patients with atrial fibrillation (AF) at risk for ischemic stroke will be evaluated by measuring change in the percentage of patients treated with OAC, from baseline to Final Collection Periods.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2017-12-29 |
| Est. Completion | 2019-12-03 |
Why NCT03382613 stopped before completion
NCT03382613 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03382613 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03382613 about?
NCT03382613 is a clinical study titled "A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation". The purpose of this study is to evaluate the impact of a hospital quality improvement (QI) program on the use of guideline-recommended oral anticoagulants (OAC) in hospitalized patients with atrial fibrillation (AF) at risk for ischemic stroke. Specifically, the study will determine whether the inte...
What is the current status of trial NCT03382613?
This trial is currently terminated. The enrollment target is 2,000 participants. The study started on 2017-12-29. Estimated completion is 2019-12-03.
Who is sponsoring clinical trial NCT03382613?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI